Nippon Shinyaku and Pfizer conclude exclusive sales promotion on Tramal

30 September 2013

Japanese mid-size drugmaker Nippon Shinyaku (TYO: 4526) and the local subsidiary of global pharma behemoth Pfizer (NYSE: PFE) have concluded an exclusive sales promotion consignment contract in Japan for Tramal Capsule (tramadol hydrochloride), a cancer pain and chronic pain treatment for which Nippon Shinyaku holds the marketing rights, as well as NS-24 (once-daily tramadol hydrochloride), a new treatment under development by Nippon Shinyaku for the same indications.

According to this contract, Nippon Shinyaku will commission Pfizer with the exclusive sales promotion of Tramal and NS-24. While Pfizer becomes a single sales promoter as of December 1, 2013, Nippon Shinyaku will continue to act as a distributor.

Tramal is a non-narcotic opioid analgesic which acts as μ-opioid receptor agonist and monoaminergic action (reuptake inhibition of noradrenaline and serotonin), which Nippon Shinyaku launched in Japan in September 2010.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK